



## Using Ivermectin for COVID-19 virus

There have been many reports recently about oral ivermectin treating COVID 19 infections, reducing mortality, speeding recovery and possibly preventing infections after exposure to the COVID-19 virus.

Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug that is used to treat several neglected tropical diseases, including onchocerciasis and helminthiasis.

Oral Ivermectin is well-tolerated when used as directed for its approved indication, strongyloidiasis an infection caused by roundworm or off-label for lice and scabies. Adverse effects include nausea, diarrhea, dizziness, itching <sup>1</sup>

In vitro studies of Ivermectin has been shown to inhibit the replication of SARS-CoV-2 virus in cell cultures.<sup>2</sup> However pharmacokinetic and pharmacodynamic studies show achieving this level for its antiviral effect would require doses up to 100-fold higher than those approved in humans.<sup>3</sup> Overdose, can cause vomiting, hypotension, ataxia, seizures, coma, and death.

Several meta-analyses have highlighted that the effect of ivermectin in patients with COVID-19 remains uncertain because of a lack of high-quality data. The studies could not find benefit for mortality, recovery, or viral clearance or as prophylaxis. <sup>4,5</sup>

The American Medical Association, American Society of Health-System Pharmacists, and the American Pharmacists Association oppose ivermectin use for COVID-19 except in a clinical trial. The National Institute of Health (NIH) guidance recommends neither for nor against ivermectin for COVID-19 treatment due to insufficient evidence.<sup>1</sup>

Aetna Medicaid covers Ivermectin in doses and durations consistent with FDA-approved indications. Uses that are not approved, i.e. off-label and that are not supported in standard reference compendia as accepted safe and effective treatments are considered experimental and/or investigational. Such therapies are not a covered benefit.

### References

1. NIH. Coronavirus disease 2019 (COVID-19). Treatment guidelines. Last updated October 27, 2021. <https://covid19treatmentguidelines.nih.gov/>. (Accessed November 13, 2021)
2. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178:104787. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32251768>.
3. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. *J Clin Pharmacol.* 2002;42(10):1122-1133. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12362927>.
4. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. *Clin Infect Dis* 2021 Jun 28. doi: 10.1093/cid/ciab591.
5. Popp M, Stegemann M, Metzendorf MI. et al. Ivermectin for preventing and treating COVID-19. *Cochrane Database Syst Rev* 2021;(7):CD015017.